Daniel Brodie
Auto-generated profile, based on publicly available information

Daniel Brodie

Division of Pulmonary and Critical Care Medicine, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ANAni Nalbandian
Ani Nalbandian
KSKartik Sehgal
Kartik Sehgal
AGAakriti Gupta
Aakriti Gupta
MMMahesh V. Madhavan
Mahesh V. Madhavan
CMClaire McGroder
Claire McGroder
EWElaine Y. Wan
Elaine Y. Wan

7 May 2021 in ASAIO Journal
Verified
Journal Article
Closed access
JTJoseph Tonna
Joseph Tonna
DADarryl Abrams
Darryl Abrams
DBDaniel Brodie
Daniel Brodie
JGJohn C. Greenwood
John C. Greenwood
JMJose Alfonso Rubio Mateo-Sidron
Jose Alfonso Rubio Mateo-Sidron
EFEddy Fan
Eddy Fan
Disclaimer: The use of venovenous extracorporeal membrane oxygenation (VV ECMO) in adults has rapidly increased worldwide. This ELSO guideline is intended to be a practical guide to patient selection, initiation, cannulation, management, and weaning of VV ECMO for adult respiratory failure. This is a consensus document which has been updated from the previous version to provide guidance to the clinician.

1 July 2014 in JACC
Verified
Journal Article
Closed access
DADarryl Abrams
Darryl Abrams
ACAlain Combes
Alain Combes
DBDaniel Brodie
Daniel Brodie

26 February 2021 in ASAIO Journal
Verified
Journal Article
Closed access
JBJenelle Badulak
Jenelle Badulak
MAMarta Velia Antonini
Marta Velia Antonini
CSChristine M Stead
Christine M Stead
LSLara Shekerdemian
Lara Shekerdemian
LRLakshmi Raman
Lakshmi Raman
DBDaniel Brodie
Daniel Brodie
Disclaimer: This is an updated guideline from the Extracorporeal Life Support Organization (ELSO) for the role of extracorporeal membrane oxygenation (ECMO) for patients with severe cardiopulmonary failure due to coronavirus disease 2019 (COVID-19). The great majority of COVID-19 patients (>90%) requiring ECMO have been supported using venovenous (V-V) ECMO for acute respiratory distress syndrome (ARDS). While COVID-19 ECMO run duration may be longer than in non-COVID-19 ECMO patients, published mortality appears to be similar between the two groups. However, data collection is ongoing, and there is a signal that overall mortality may be increasing. Conventional selection criteria for COVID-19–related ECMO should be used; however, when resources become more constrained during a pandemic, more stringent contraindications should be implemented. Formation of regional ECMO referral networks may facilitate communication, resource sharing, expedited patient referral, and mobile ECMO retrieval. There are no data to suggest deviation from conventional ECMO device or patient management when applying ECMO for COVID-19 patients. Rarely, children may require ECMO support for COVID-19–related ARDS, myocarditis, or multisystem inflammatory syndrome in children (MIS-C); conventional selection criteria and management practices should be the standard. We strongly encourage participation in data submission to investigate the optimal use of ECMO for COVID-19.

5 January 2024 in ASAIO Journal
Verified
Journal Article
Closed access
JTJoseph Tonna
Joseph Tonna
PBPhilip S. Boonstra
Philip S. Boonstra
GMGraeme MacLaren
Graeme MacLaren
MPMatthew Paden
Matthew Paden
DBDaniel Brodie
Daniel Brodie
OGon behalf of the Extracorporeal Life Support Organization (ELSO) Member Centers Group
on behalf of the Extracorporeal Life Support Organization (ELSO) Member Centers Group
The Extracorporeal Life Support Organization (ELSO) maintains the world’s largest extracorporeal membrane oxygenation (ECMO) registry by volume, center participation, and international scope. This 2022 ELSO Registry Report describes the program characteristics of ECMO centers, processes of ECMO care, and reported outcomes. Neonates (0–28 days), children (29 days–17 years), and adults (≥18 years) supported with ECMO from 2009 through 2022 and reported to the ELSO Registry were included. This report describes adjunctive therapies, support modes, treatments, complications, and survival outcomes. Data are presented descriptively as counts and percent or median and interquartile range (IQR) by year, group, or level. Missing values were excluded before calculating descriptive statistics. Complications are reported per 1,000 ECMO hours. From 2009 to 2022, 154,568 ECMO runs were entered into the ELSO Registry. Seven hundred and eighty centers submitted data during this time (557 in 2022). Since 2009, the median annual number of adult ECMO runs per center per year increased from 4 to 15, whereas for pediatric and neonatal runs, the rate decreased from 12 to 7. Over 50% of patients were transferred to the reporting ECMO center; 20% of these patients were transported with ECMO. The use of prone positioning before respiratory ECMO increased from 15% (2019) to 44% (2021) for adults during the coronavirus disease-2019 (COVID-19) pandemic. Survival to hospital discharge was greatest at 68.5% for neonatal respiratory support and lowest at 29.5% for ECPR delivered to adults. By 2022, the Registry had enrolled its 200,000th ECMO patient and 100,000th patient discharged alive. Since its inception, the ELSO Registry has helped centers measure and compare outcomes across its member centers and strategies of care. Continued growth and development of the Registry will aim to bolster its utility to patients and centers.

27 February 2014 in Critical Care
Verified
Journal Article
Open access
PDF file
DADarryl Abrams
Darryl Abrams
JJJeffrey Javidfar
Jeffrey Javidfar
EFErica Farrand
Erica Farrand
LMLinda B Mongero
Linda B Mongero
CACara L Agerstrand
Cara L Agerstrand
DBDaniel Brodie
Daniel Brodie
Introduction: Critical illness is a well-recognized cause of neuromuscular weakness and impaired physical functioning. Physical therapy (PT) has been demonstrated to be safe and effective for critically ill patients. The impact of such an intervention on patients receiving extracorporeal membrane oxygenation (ECMO) has not been well characterized. We describe the feasibility and impact of active PT on ECMO patients. Methods: We performed a retrospective cohort study of 100 consecutive patients receiving ECMO in the medical intensive care unit of a university hospital. Results: Of the 100 patients receiving ECMO, 35 (35%) participated in active PT; 19 as bridge to transplant and 16 as bridge to recovery. Duration of ECMO was 14.3 ± 10.9 days. Patients received 7.2 ± 6.5 PT sessions while on ECMO. During PT sessions, 18 patients (51%) ambulated (median distance 175 feet, range 4 to 2,800) and 9 patients were on vasopressors. Whilst receiving ECMO, 23 patients were liberated from invasive mechanical ventilation. Of the 16 bridge to recovery patients, 14 (88%) survived to discharge; 10 bridge to transplant patients (53%) survived to transplantation, with 9 (90%) surviving to discharge. Of the 23 survivors, 13 (57%) went directly home, 8 (35%) went to acute rehabilitation, and 2 (9%) went to subacute rehabilitation. There were no PT-related complications. Conclusions: Active PT, including ambulation, can be achieved safely and reliably in ECMO patients when an experienced, multidisciplinary team is utilized. More research is needed to define the barriers to PT and the impact on survival and long-term functional, neurocognitive outcomes in this population.